Drugs / AMG 553
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03904069 | Mar 2023 → Aug 2030 | acute myeloid leukemia | Amgen | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 553 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03904069 ↗ |
| Modality | Cell therapy | “AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy” NCT03904069 ↗ |
| Route | Intravenous | “Subjects will receive IV infusion of AMG 553” NCT03904069 ↗ |
| Target | FLT3 | “FLT3 CAR-T AMG 553” NCT03904069 ↗ |